Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2006-08-22
2006-08-22
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C424S192100, C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
07094405
ABSTRACT:
Peptide constructs comprised of multideterminant T helper peptides from the envelope glycoprotein of HIV previously identified to induce proliferative responses in four different haplotypes of mice and IL-2 responses in 52-73% of HIV positive, flu positive patients (cluster peptides), were co-linearly synthesized with the peptide 18 of the V3 loop of HIV-1 gp 160, corresponding to the principal neutralizing determinant of HIV-IIIB and also shown to contain a dominant CTL epitope. Cognate help for peptide 18 antibody was elicited following a single immunization in all strains of mice which had previously responded to a T cell epitope encompassed by the peptides. In two strains of mice, the level of neutralizing antibody achieved was comparable to levels adequate for protection from homologous viral challenge in chimpanzees. After a single boost, much higher antibody titers for 90% neutralization in the range of 1:1000 to 1:16,000 were achieved. Spleen cells from mice of three distinct MHC haplotypes sharing the Ddclass I MHC molecule but with different class II molecules, immunized with the compound peptides, exhibited enhanced gp160-specific CTL activity.
REFERENCES:
patent: 0362909 (1990-04-01), None
patent: 0448095 (1991-09-01), None
patent: WO9304697 (1993-03-01), None
Ahlers et al.,J. Immunol. 150(12):5647-5665, 1993.
Berzofsky et al.,J. Clin. Invest, 88:876-884, 1991.
Bhardwaj et al.,Eur. J. Immunol. 22:2009-2016, 1992.
Defoort et al.,Proc. Natl. Acad. Sci. 89:3879-3883, 1992.
Del Val et al.,Cell 66:1145-1153, 1991.
Eisenlohr et al.,J. Exp. Med. 175:481-487, 1992.
Engelhard,Ann. Rev. Immunol. 12:181-207, 1994.
Greenstein et al.,J. Immunol. 148:3970-3977, 1992.
Hansen et al., in fundamental Immunology, Paul, ed., Raven Press; New York, pp. 609 and 612, 1993.
Hart et al.,Proc. Natl. Acad. Sci. 88:9448-9452, 1991.
Hart et al.,J. Immunol. 145:2677-2685, 1990.
Javaherian et al.,Proceedings of the Natl. Acad. of Sciences of the USA 86(17):6768-6772, 1989.
Lasarte et al.,Cellular Immunol. 141:211-218, 1992.
Palker et al.,J. Immunol. 142:3612-3619, 1989.
Partidos et al.,Immunol. 77:262-266, 1992.
Rovinski et al.,J. Virol. 66(7):4003-4012, 1992.
Sarobe et al.,Eur. J. Immunol. 21:1553-1558, 1991.
Schrier et al.,J. Virol. 62(8):2531-2536, 1988.
Strognin, in Laboratory Diagnosis of Viral Infections, Lennette, ed., Marcel Dekker, Inc., New York, pp. 211-219, 1992.
Ahlers Jeffrey D.
Berzofsky Jay A.
Nara Peter
Pendleton C. David
Shirai Mutsunori
Parkin Jeffrey S.
The United States of America as represented by the Secretary of
Towsend and Townsend and Crew LLP
LandOfFree
Peptides which elicit a high neutralizing antibody titer,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides which elicit a high neutralizing antibody titer,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides which elicit a high neutralizing antibody titer,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3645411